<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Infectious complications of intravesical BCG immunotherapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Infectious complications of intravesical BCG immunotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Infectious complications of intravesical BCG immunotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael A O'Donnell, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pamela H Orr, MD, MSc, FRCPC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seth P Lerner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intravesical administration of Bacillus Calmette-Guérin (BCG), a live attenuated strain of <em>Mycobacterium bovis</em>, is an adjunctive therapy for treatment of non-muscle invasive bladder cancer. The organism is referred to as <em>M. bovis</em> BCG. Issues related to treatment of patients with bladder cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer", section on 'Bacillus Calmette-Guerin'</a>.)</p><p><a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">Intravesical BCG</a> is usually well tolerated; uncommonly, severe local and systemic complications can occur [<a href="#rid1">1-5</a>]. Issues related to infectious complications of BCG immunotherapy will be reviewed here. Issues related to noninfectious complications of BCG are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>BCG was initially developed as a vaccine against tuberculosis. (See  <a class="medical medical_review" href="/z/d/html/8022.html" rel="external">"Prevention of tuberculosis: BCG immunization and nutritional supplementation", section on 'Bacille Calmette-Guérin vaccine'</a>.)</p><p>The possibility of a role for BCG in cancer treatment was first raised in the 1920s, when an autopsy study noted a lower frequency of cancer in patients with tuberculosis and a higher frequency of tuberculosis among cancer survivors [<a href="#rid6">6</a>]. In the 1930s, a profound stimulatory effect of BCG on the reticuloendothelial system was described; in the 1980s, a lower incidence of leukemia was observed among children who had received neonatal BCG immunization [<a href="#rid2">2,4</a>]. </p><p>The mechanism of BCG as an immunotherapeutic agent for treatment of bladder cancer is not fully understood; it is thought to induce local immune activation, leading to death of tumor cells. This is discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer", section on 'Mechanism of action of Bacillus Calmette-Guerin'</a>.)</p><p>Complications associated with BCG immunotherapy may represent a hypersensitivity reaction, active infection, or both. In some case reports, granulomas have been observed on bronchial or pulmonary biopsy, with negative staining and culture for acid-fast bacilli, negative molecular tests, and favorable clinical response to administration of systemic corticosteroids; these findings are suggestive of hypersensitivity reaction [<a href="#rid3">3,7,8</a>]. However, in other case reports, viable organisms and/or positive molecular tests have been observed in a variety of tissues outside the bladder [<a href="#rid9">9-21</a>]. Organisms likely gain access to the systemic circulation via uroepithelial disruption, leading to dissemination. (See  <a class="medical medical_review" href="/z/d/html/8023.html" rel="external">"Tuberculosis: Natural history, microbiology, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>BCG infection at any site is relatively rare [<a href="#rid5">5,22</a>]. Between 2004 and 2015, 118 cases of BCG infection were reported to the US National Tuberculosis Surveillance System [<a href="#rid22">22</a>]. </p><p><a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">Intravesical BCG</a> is associated with infectious complications in approximately 1 to 5 percent of cases [<a href="#rid1">1,5,23</a>]. In one retrospective cohort study including 6753 patients treated with intravesical BCG, BCG infection developed in 1 percent of cases [<a href="#rid5">5</a>]. In a review including more than 250 patients, infectious complications were observed in 4.3 percent of cases [<a href="#rid1">1</a>]. </p><p>Risk markers for systemic infection associated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> include [<a href="#rid24">24-26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Traumatic catheterization</p><p class="bulletIndent1"><span class="glyph">●</span>Active cystitis</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent gross hematuria following transurethral surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression </p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥70 years</p><p></p><p>The likelihood of developing BCG-related complications appears to be more dependent on host characteristics (such as presence of bladder mucosal damage or presence of immunosuppression) than on other factors including the BCG dose, the number of BCG instillations, or the time interval since the transurethral surgery [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2386748650"><span class="h2">Timing</span><span class="headingEndMark"> — </span>The clinical manifestations of early-onset infection (within ≤3 months of BCG instillation) differ from those of delayed-onset infection (&gt;3 months after BCG instillation; may occur months to years later). Data are limited to small series and case reports [<a href="#rid24">24,27-33</a>]. </p><p>Early-onset BCG infection often presents with systemic manifestations. In small series describing patients with early-onset infection, manifestations included constitutional symptoms (fever, sweats, weight loss) as well as pneumonitis and hepatitis [<a href="#rid30">30,31</a>]. </p><p>Delayed-onset BCG infection often presents with localized disease and positive urine mycobacterial cultures; less commonly, delayed-onset systemic disease can occur [<a href="#rid27">27,30-33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study including 15 patients with delayed-onset involvement, localized disease was observed in 75 percent of patients; sites of involvement included the genitourinary tract, vascular structures, bone, retroperitoneum, and chest wall [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series including seven patients with delayed-onset infection, isolated bladder symptoms (frequency, urgency, gross hematuria, and incontinence) were observed in three cases, systemic symptoms (constitutional symptoms as well as cough, altered mental status, arthritis) were observed in two cases, one patient had systemic and localized symptoms, and one patient was asymptomatic with a nonhealing mucosal ulcer on cystoscopy [<a href="#rid31">31</a>]. Urine mycobacterial culture was positive in 90 percent of cases. The average time from BCG instillation to diagnosis was 35 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series including 13 patients with delayed presentation of bladder lesions on routine follow-up cystoscopy (median 8 months after BCG instillation), half were asymptomatic; the remainder had urgency, frequency, and/or pain [<a href="#rid27">27</a>]. All patients had a focal granulomatous or ulcerative lesion in the bladder, and all had positive urine mycobacterial cultures.</p><p></p><p class="headingAnchor" id="H1687864700"><span class="h2">Forms</span><span class="headingEndMark"> — </span>The types of systemic and localized infections in a review including 282 cases of BCG infection associated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> administration are summarized in the table  (<a class="graphic graphic_table graphicRef104208" href="/z/d/graphic/104208.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. </p><p>The median time from transurethral surgery to BCG instillation was 30 days, the median number of BCG instillations was six, and the median time from last instillation to onset of infection was 13.5 days (interquartile range 2 to 195 days). </p><p class="headingAnchor" id="H5"><span class="h3">Localized disease</span><span class="headingEndMark"> — </span>Localized disease typically presents with delayed-onset infection (&gt;3 months after BCG instillation; may occur months to years later) involving the genitourinary tract; manifestations may include [<a href="#rid2">2,34-38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cystitis</p><p class="bulletIndent1"><span class="glyph">●</span>Bladder contracture</p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous prostatitis</p><p class="bulletIndent1"><span class="glyph">●</span>Prostate abscess</p><p class="bulletIndent1"><span class="glyph">●</span>Epididymo-orchitis</p><p class="bulletIndent1"><span class="glyph">●</span>Testicular abscess</p><p class="bulletIndent1"><span class="glyph">●</span>Pyelonephritis</p><p class="bulletIndent1"><span class="glyph">●</span>Renal abscess</p><p class="bulletIndent1"><span class="glyph">●</span>Ureteral stricture</p><p class="bulletIndent1"><span class="glyph">●</span>Penile granuloma </p><p></p><p>Most patients develop symptoms of bladder irritation, such as dysuria and frequency, within two to four hours of BCG instillation. These symptoms may be accompanied by low-grade fever and malaise, especially in patients who have received prior intravesicular instillations [<a href="#rid7">7</a>]. Such manifestations generally resolve within 48 hours. Persistence or escalation of genitourinary symptoms should prompt investigation of active infection, due to BCG or other bacterial pathogens.</p><p>Symptoms due to localized disease associated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> may be indistinguishable from those attributable to non-BCG-related bacterial urinary tract infection (UTI). For this reason, clinical suspicion for <em>M. bovis</em> BCG as a potential causative agent must be maintained in patients presenting with UTI symptoms within an appropriate clinical context.</p><p>Persistent cystitis (manifested as severe urgency, frequency, and dysuria) even after discontinuing BCG suggest development of BCG cystitis. This is an uncommon condition that presents with systemic symptoms and sterile pyuria (eg abnormal urinalysis with negative bacterial cultures). Symptoms may continue for weeks to months despite antimycobacterial therapy, suggesting a hypersensitivity component. Cystoscopically, the bladder appears red, beefy, and irritated, typically with acute and granulomatous inflammation [<a href="#rid31">31,39</a>]. </p><p><em>M. bovis</em> BCG infection can spread locally from the bladder to involve other structures within the genitourinary tract. Such infections include granulomatous ulceration of the glans penis, prostatitis, epididymitis, ureteral obstruction, bladder contracture, and renal abscess [<a href="#rid34">34-36</a>]. </p><p>Prostatitis due to <em>M. bovis</em> BCG is relatively common but is often asymptomatic. In one series including 12 patients who underwent cystoprostatectomy for management of invasive bladder cancer following prior treatment with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a>, granulomatous prostatitis was observed in 9 cases; of these, 7 had positive acid fast bacilli (AFB) stain [<a href="#rid40">40</a>]. </p><p><a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">Intravesical BCG</a> administration may be associated with transiently elevated prostate specific antigen in up to 40 percent of cases; this finding typically reverts to normal within three months [<a href="#rid41">41</a>]. </p><p><em>M. bovis</em> BCG infection may present years after BCG intravesical therapy [<a href="#rid37">37</a>]. Therefore, clinical suspicion must be maintained in patients who have had BCG therapy. In one report of eight cases, the authors describe both early and late (&gt;1 year) presentations of <em>M. bovis</em> BCG infection; the late disease involved local granulomatous infection in the genitourinary tract, usually with positive mycobacterial cultures [<a href="#rid30">30</a>]. Similarly, a late ulcerative inflammatory cystitis has been reported to be associated with persistent local <em>M. bovis</em> BCG infection [<a href="#rid27">27</a>].  </p><p class="headingAnchor" id="H7"><span class="h3">Systemic complications</span><span class="headingEndMark"> — </span>Systemic disease occurs when BCG disseminates outside the genitourinary tract via the bloodstream to other sites [<a href="#rid2">2,11,30</a>]. Systemic complications often present with early-onset infection (within ≤3 months of BCG instillation) but onset of infection may be delayed (&gt;3 months after BCG instillation; may occur months to years later).</p><p>Disseminated BCG infection (in the form of miliary disease, sepsis, or fever associated with organ involvement) is the most commonly reported form of <em>M. bovis</em> BCG infection in the literature; in one review, it accounted for one-third of cases [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H8"><span class="h4">Sepsis syndrome</span><span class="headingEndMark"> — </span>Onset of a sepsis syndrome soon after BCG instillation has been described; manifestations include a characteristic relapsing late diurnal fever with drenching night sweats and rigors that may progress rapidly to hypotension, disseminated intravascular coagulation, and respiratory failure [<a href="#rid35">35</a>]. The mechanism is likely attributable to cytokine release [<a href="#rid42">42</a>]. </p><p>Cases of delayed-onset sepsis have been described years after an apparently uncomplicated BCG treatment. Compromise of the immune system (eg, due to administration of systemic glucocorticoids or immunosuppressants) may cause reactivation of a dormant focus [<a href="#rid24">24,43</a>].</p><p class="headingAnchor" id="H1728192311"><span class="h4">Pulmonary</span><span class="headingEndMark"> — </span>Dyspnea may be present, and progression to respiratory compromise can occur. In addition, relatively asymptomatic or subclinical cases have been described [<a href="#rid33">33,44</a>]. </p><p>In some patients with disseminated BCG infection, chest radiography or computed tomography (CT) demonstrates a miliary nodular or interstitial pattern, sometimes associated with hilar adenopathy; these findings are observed most frequently in association with sepsis [<a href="#rid8">8,45</a>]. The sensitivity of chest radiography is limited; in one series including 216 patients with systemic BCG infection, chest radiography failed to reveal a miliary pattern in about 25 percent of patients with pneumonitis subsequently identified via CT scan [<a href="#rid1">1</a>]. </p><p>Other pulmonary manifestations including pleural effusion have been described [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H9"><span class="h4">Hepatic</span><span class="headingEndMark"> — </span>Granulomatous hepatitis is a rare complication of <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a>; it may arise as an early or delayed complication [<a href="#rid7">7,47,48</a>]. Clinical manifestations include fever, anorexia, and jaundice. This condition may occur in isolation or in association with disease at other sites (eg, genitourinary tract, respiratory tract, vascular sites) [<a href="#rid49">49,50</a>]. </p><p class="headingAnchor" id="H3813890580"><span class="h4">Musculoskeletal</span><span class="headingEndMark"> — </span>Osteomyelitis is a rare complication of <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a>. Most reported cases involve the spine, presumably due to spread from the urinary tract via the Batson plexus [<a href="#rid51">51-53</a>]. Bony involvement outside the spine has also been described. </p><p>Patients with spondylitis present with back pain and may have motor weakness. Vertebral infection may be accompanied by psoas abscess; in such cases, hip pain and inability to straighten the leg may be observed [<a href="#rid53">53</a>]. In addition, vertebral infection may also be accompanied by mycotic vascular infection [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/7658.html" rel="external">"Bone and joint tuberculosis", section on 'Spondylitis (Pott disease)'</a> and  <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">"Vertebral osteomyelitis and discitis in adults"</a>.)</p><p>Osteoarticular complications of <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> are rare; they include reactive arthritis and osteoarticular infection [<a href="#rid55">55</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with reactive arthritis typically present within a few weeks after BCG instillation with oligoarthritis or polyarthritis, predominantly of the lower extremities [<a href="#rid56">56,57</a>]. Associated genitourinary symptoms include frequency, cystitis, and hematuria. In addition, ocular manifestations may be observed; these include conjunctivitis and uveitis (Reiter syndrome) [<a href="#rid58">58</a>]. In one review including 43 cases of reactive arthritis, 53 percent of patients were positive for HLA-B27, and at least 19 percent had axial pain (compatible with spondyloarthritis) [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">"Reactive arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monoarthritis following <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> instillation should prompt suspicion for joint infection [<a href="#rid55">55</a>]. Septic arthritis may be due to bacterial infection or <em>M. bovis</em> infection. </p><p></p><p>Psoas abscess may occur as a complication of <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> installation, either alone or in combination with vertebral osteomyelitis and/or vascular infection [<a href="#rid14">14</a>].</p><p>Case reports of orthopedic hardware infection have been described [<a href="#rid59">59-62</a>]. </p><p class="headingAnchor" id="H3713216527"><span class="h4">Vascular</span><span class="headingEndMark"> — </span>Vascular complications associated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> are rare. Case reports have described mycotic aneurysms involving the abdominal or thoracic aorta; these include one with subsequent involvement of an aortic graft, and another with involvement of multiple sites including a carotid aneurysm [<a href="#rid15">15,21,50,63</a>]. Vascular involvement may develop via hematogenous seeding of the vasa vasorum of the arterial wall, or as a result of contiguous extension from an adjacent site (such as a vertebral body or perivascular lymph nodes) [<a href="#rid1">1</a>].</p><p>Clinical manifestations include low-grade fever, malaise, and weight loss. . Vascular involvement was associated with mortality rate of 16 percent in one series [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H13"><span class="h4">Other manifestations</span><span class="headingEndMark"> — </span>Other manifestations of active infection that may be caused by BCG include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever of unknown origin accompanied by night sweats, anorexia, fatigue, weight loss, and pancytopenia occurred in two patients who had granulomas in bone marrow; <em>M. bovis</em> was recovered in bone marrow cultures [<a href="#rid17">17</a>]. In another series including 10 patients with similar presentations, nine patients had noncaseating bone marrow granulomas while the remainder had caseating granulomas; bone marrow culture was positive in four cases [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic manifestations include cytopenia with granulomatous bone marrow involvement [<a href="#rid32">32</a>] and immune thrombocytopenia with cryoglobulinemia [<a href="#rid64">64</a>]. Hemophagocytic syndrome associated with bone marrow involvement, anemia, high plasma ferritin, and high triglycerides has been noted in case reports [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) involvement by BCG has been observed in a small number of cases [<a href="#rid1">1,5,20,31,66,67</a>]; both early-onset and delayed-onset presentations have been described. Manifestations include meningitis, brain tuberculomas, cerebellar abscess, small vessel vasculitis, and Guillain-Barre syndrome. Symptoms may be vague, including dizziness, ataxia, mental status changes, and headaches with or without associated fevers, night sweats, and weight loss; these may persist for weeks in a relapsing pattern. Focal neurologic signs may not be present until late in the course of the disease. Cerebrospinal fluid findings are as described in CNS disease due to tuberculosis (lymphocytic pleocytosis, elevated protein levels, low glucose) [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">"Central nervous system tuberculosis: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Case reports of endophthalmitis and choroidal tuberculoma have been described in patients treated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> [<a href="#rid18">18,19,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Id-like (autoeczematization) skin rash associated with BCG administration has been described [<a href="#rid69">69</a>]. </p><p></p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Localized BCG infection should be suspected in patients treated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> who present with either early- or delayed-onset manifestations (&gt;3 months after BCG instillation) involving the genitourinary tract (see <a class="local">'Localized disease'</a> above). Systemic BCG infection should be suspected in patients treated with intravesical BCG who present with systemic manifestations, particularly within ≤3 months of BCG instillation (see <a class="local">'Systemic complications'</a> above).</p><p>Definitive diagnosis of BCG infection may be established via positive <em>M. bovis</em> BCG culture (of bodily fluids and/or tissue from involved sites, when obtainable); however, the sensitivity of AFB stain and culture is subject to limitations. Therefore, in the appropriate clinical and epidemiologic setting and in the absence of evidence for an alternative etiology of these findings, a presumptive diagnosis may be made in the setting of positive acid-fast bacilli (AFB) smear (of bodily fluids or tissue from involved sites), histopathology from an involved site demonstrating granulomas, and/or positive nucleic acid amplification (NAA) test on fluid or tissue. (See <a class="local">'Differential diagnosis'</a> below.) </p><p>Diagnostic evaluation includes obtaining bodily fluids (urine, blood, and fluid from any other involved sites) and/or tissue for AFB stain, mycobacterial culture, mycobacterial NAA test, Gram stain, bacterial culture, fungal stain, and fungal culture, as well as other studies guided by the sample type (as an example, patients with joint involvement should have synovial fluid sent for cell count and crystal evaluation). In addition, patients with systemic symptoms should have chest imaging (computed tomography or magnetic resonance imaging preferred over conventional radiography) to evaluate for pulmonary involvement. (See <a class="local">'Pulmonary'</a> above.)</p><p>The sensitivity of AFB smear, mycobacterial culture, and molecular testing is limited. In a review of 282 cases of BCG infection associated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> administration (including 216 patients with systemic disease), AFB staining was positive in 25 percent of cases, mycobacterial culture was positive in 41 percent of cases, and molecular testing was positive in 42 percent of cases [<a href="#rid1">1</a>]. Microbiologic diagnosis was established more frequently among patients with localized BCG infection (53 versus 38 percent). Among patients who underwent biopsy, histopathology demonstrated granulomatous inflammation in 86 percent of cases; the highest yield biopsy sites were lung, bone marrow, and liver. Caseous necrosis is typically absent [<a href="#rid3">3</a>].</p><p>NAA tests cannot differentiate between members of the <em>Mycobacterium tuberculosis</em> complex. </p><p>In the setting of noninvasive workup that yields no definitive diagnosis, the decision whether to pursue biopsy or initiate empiric anti-<em>M. bovis</em> BCG treatment involves careful consideration of risks and benefits. If biopsy is pursued, separate specimens should be sent for microbiology (including AFB stain, mycobacterial culture, mycobacterial molecular testing, Gram stain, bacterial culture, fungal stain, and fungal culture) and histopathology.</p><p>It is possible to use molecular typing to compare the strain of <em>M. bovis</em> BCG isolated from a patient and the strain (if known) that was used in that individual’s <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> treatment [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H509187374"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Mild post-instillation symptoms – Minor symptoms following BCG administration are common (up to 85 percent of patients) [<a href="#rid70">70</a>]. These include fever, malaise, and bladder irritation (urination frequency, dysuria, or mild hematuria) within a few hours of BCG instillation [<a href="#rid2">2</a>]. Urinalysis shows nonspecific inflammation and cultures do not demonstrate evidence of infection. Such manifestations generally resolve within 48 hours and reflect a hypersensitivity reaction rather than an infectious complication of BCG. Management consists of analgesics and/or non-steroidal anti-inflammatory drugs [<a href="#rid1">1</a>]. Symptoms usually resolve within 48 hours, after which BCG may be resumed.</p><p></p><p class="bulletIndent1">Occasionally, temperature &gt;39.0°C (102.5°F) may develop acutely following BCG therapy, but does not necessarily signify active <em>M. bovis</em> BCG infection. In this setting, it may be impossible to distinguish an infectious versus a noninfectious event. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial infection – Presence of genitourinary tract and/or systemic symptoms may reflect non-BCG bacterial infection. Up to 20 percent of patients receiving <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> develop a bacterial urinary tract infection at some point during treatment [<a href="#rid71">71</a>]. Bodily fluids and tissues should be sent for Gram stain and bacterial culture (in addition to workup for mycobacterial infection). (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2129.html" rel="external">"Overview of infected (mycotic) arterial aneurysm"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungal infection – Presence of genitourinary tract and/or systemic symptoms may reflect fungal infection. Fungal infections such as histoplasmosis and blastomycosis are endemic in certain geographic regions and may cause genitourinary tract infection. If fungal urinary tract infection is suspected, urine may be sent for fungal stain and culture. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis"</a> and  <a class="medical medical_review" href="/z/d/html/2461.html" rel="external">"Diagnosis and treatment of disseminated histoplasmosis in patients without HIV"</a> and  <a class="medical medical_review" href="/z/d/html/2437.html" rel="external">"Clinical manifestations and diagnosis of blastomycosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternative mycobacterial infection – Other mycobacterial infections include <em>M. tuberculosis</em>, <em>M. bovis</em>, and nontuberculous mycobacterial infection. These may distinguished based on epidemiologic factors and results from mycobacterial culture and molecular tests. The <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) and interferon-gamma release assay (IGRA) are tools designed for diagnosis of tuberculosis infection; in the setting of tuberculosis infection, one or both tests may be positive. In the setting of BCG infection, the TST may be positive but the IGRA is negative, since IGRA assay antigens are not shared with BCG [<a href="#rid72">72</a>]. However, neither TST nor IGRA definitively establishes or rules out either condition; therefore these tests are of little help in the diagnosis of active disease due to <em>M. bovis</em> BCG or <em>M. tuberculosis</em>. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8006.html" rel="external">"Mycobacterium bovis"</a> and  <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternative causes of granulomatous disease – Alternative causes of granulomatous lung disease include sarcoidosis and hypersensitivity pneumonitis. Alternative infectious causes of hepatic granulomas include fungal disease, Q fever, and brucellosis. Alternative noninfectious causes of hepatic granulomas include sarcoidosis, malignancy, and drug reaction. (See  <a class="medical medical_review" href="/z/d/html/16921.html" rel="external">"Interpretation of lung biopsy results in interstitial lung disease", section on 'Granulomatous lung diseases'</a> and  <a class="medical medical_review" href="/z/d/html/3582.html" rel="external">"Evaluation of the adult patient with hepatic granuloma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy – Radiographic findings of localized or systemic disease may be difficult to distinguish from malignancy localized to genitourinary tract (such as renal cell carcinoma) or metastatic disease (eg, to the spine). These conditions are distinguished via biopsy. </p><p></p><p class="headingAnchor" id="H15"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The optimal approach to treatment of infectious complications associated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> is uncertain; there are no clinical trials. The approach is guided by case series and clinical experience with treatment of infection due to <em>M. bovis</em> BCG, which is susceptible to most antimycobacterial drugs except <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a> and <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">cycloserine</a> [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/8006.html" rel="external">"Mycobacterium bovis", section on 'Treatment'</a>.)</p><p>The approach to treatment depends on the clinical presentation, as discussed in the following sections. </p><p class="headingAnchor" id="H2723002372"><span class="h2">Localized disease</span><span class="headingEndMark"> — </span>For patients with symptoms localized to the genitourinary tract, management of infection consists of antimycobacterial therapy; in addition, surgical evaluation is warranted in the setting of abscess or genitourinary tract obstruction [<a href="#rid1">1</a>]. </p><p>In cases of severe BCG cystitis, systemic steroids (in the form of a three to six-week [rapid to slow] <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper) can provide rapid and durable relief from unremitting cystitis symptoms [<a href="#rid31">31,39</a>]. Given risk for potentiating BCG spread, the patient should be maintained on antimycobacterial therapy while on steroids.</p><p>The optimal antimycobacterial regimen is uncertain; management should include involvement of an expert in management of mycobacterial infections. Patients with <em>M. bovis</em> BCG infection secondary to <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> therapy are treated with the same antituberculous medications used to treat <em>M. bovis</em> infection from other sources. Specifically, this involves an initial phase of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, followed by a continuation phase of isoniazid and rifampin, as discussed elsewhere [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/8006.html" rel="external">"Mycobacterium bovis", section on 'Treatment'</a>.)</p><p>If susceptibility data are available, the regimen should be tailored accordingly. In the setting of concern for liver toxicity, alternative antimycobacterial agents including fluoroquinolones and <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> may be considered. The duration of therapy depends on disease severity and clinical response.</p><p>In cases in which it is not clear whether the infection is due to <em>M. bovis</em> BCG or another mycobacterial species, the treatment regimen may need to be broadened to cover more than one potential microbiologic diagnosis [<a href="#rid43">43</a>].</p><p>For patients with persistent epididymo-orchitis despite antimycobacterial therapy, epididymectomy and/or orchiectomy may be warranted.</p><p>Issues related to further management of bladder cancer are discussed below. (See <a class="local">'Further cancer treatment'</a> below.)</p><p class="headingAnchor" id="H854235805"><span class="h2">Systemic disease</span><span class="headingEndMark"> — </span>For patients with systemic symptoms, management consists of antimycobacterial therapy, with addition of glucocorticoids in some circumstances [<a href="#rid1">1</a>]. In addition, surgical evaluation is warranted in the setting of abscess, genitourinary tract obstruction, vascular infection, or infection involving a prosthetic device. </p><p>The optimal antimycobacterial regimen is uncertain; management should include involvement of an expert in management of mycobacterial infections. Patients with <em>M. bovis</em> BCG infection secondary to <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> therapy are treated with the same antimycobacterial medications used to treat <em>M. bovis</em> infection from other sources. Specifically, this involves an initial phase of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, followed by a continuation phase of isoniazid and rifampin, as discussed elsewhere [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/8006.html" rel="external">"Mycobacterium bovis", section on 'Treatment'</a>.)</p><p>If susceptibility data are available, the regimen should be tailored accordingly. In the setting of concern for liver toxicity, alternative antimycobacterial agents including fluoroquinolones and <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a> may be considered. The duration of therapy depends on disease severity and clinical response.</p><p>In cases in which it is not clear whether the infection is due to <em>M. bovis</em> BCG or another mycobacterial species, the treatment regimen may need to be broadened to cover more than one potential microbiologic diagnosis [<a href="#rid43">43</a>].</p><p>In the setting of extensive miliary involvement and/or respiratory failure, case reports describe the use of glucocorticoids administered concomitantly with antimycobacterial agents, based on the potential role of hypersensitivity in the pathogenesis of the disease [<a href="#rid1">1,23,39,70,74,75</a>]. In cases in which hypersensitivity is thought to play a significant role in the patient’s illness, we suggest concomitant glucocorticoid therapy if potential benefit is felt to likely outweigh potential risk [<a href="#rid1">1,70</a>]. Use of glucocorticoids has been associated with clinical improvement in case reports [<a href="#rid39">39,74-76</a>]. </p><p>There is no standard regimen for administration of adjunctive glucocorticoids; <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg orally daily for three to five days, followed by a gradual taper over a few weeks has been described. </p><p>Issues related to further management of bladder cancer are discussed below. (See <a class="local">'Further cancer treatment'</a> below.)</p><p class="headingAnchor" id="H2293082099"><span class="h2">Reactive arthritis or uveitis</span><span class="headingEndMark"> — </span>For patients presenting with reactive arthritis or uveitis only, <strong>without </strong>signs of localized or systemic infection, antimycobacterial treatment is not administered [<a href="#rid1">1</a>]. Such patients should be managed with involvement of a clinician with expertise in these conditions. [<a href="#rid56">56</a>]. The approach to patients with reactive arthritis and uveitis, in general, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">"Reactive arthritis", section on 'Treatment of arthritis'</a> and  <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">"Uveitis: Treatment"</a>.)</p><p>Following resolution of symptoms, BCG instillations may be resumed if benefit exceeds risk. </p><p class="headingAnchor" id="H324409171"><span class="h2">Further cancer treatment</span><span class="headingEndMark"> — </span>Among individuals with infectious complications due to intravesicular BCG, the risk of repeat administration is uncertain; data are lacking. For patients who have experienced systemic BCG infection, we advise against repeat use of <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a>, given potential risk of a recurrent episode [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/98347.html" rel="external">"Management of recurrent or persistent non-muscle invasive bladder cancer"</a>.)</p><p class="headingAnchor" id="H693034562"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>In a review including 282 cases of BCG infection associated with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> administration (including 216 patients with systemic disease), attributable mortality was 5.4 percent; long-term complications occurred in 7.4 percent of cases (most commonly permanent loss of visual acuity, chronic arthralgia, and end-stage kidney disease) [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H18"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Patients with breaks in the urogenital epithelium (due to traumatic catheterization, active cystitis, or persistent gross hematuria following transurethral surgery) should have BCG instillation deferred for at least two to three weeks [<a href="#rid1">1</a>]. </p><p>There are no proven interventions for preventing infectious complications associated with administration <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a>. Screening urinalysis in asymptomatic patients prior to BCG administration has not been shown to reduce infectious complications [<a href="#rid77">77</a>], and patients with asymptomatic bacteriuria do not warrant antibiotic treatment [<a href="#rid78">78</a>].</p><p>There is no role for routine prophylactic administration of antimycobacterial therapy concurrently with <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a>. Such an intervention could reduce the anti-tumor effect of BCG, given that live BCG requires replication to induce a host immune response. In one non-blinded randomized trial evaluating the efficacy prophylactic <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, no reduction in infectious complications of BCG was observed, with low incidence in both groups [<a href="#rid79">79</a>]; in addition, disseminated infection has been observed despite use of prophylactic isoniazid [<a href="#rid48">48,52</a>].  </p><p>Reducing the dose of BCG has been proposed to reduce the likelihood of noninfectious complications; issues related to BCG dosing are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer", section on 'Dose and schedule'</a>.)</p><p class="headingAnchor" id="H2327315328"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122007.html" rel="external">"Society guideline links: Bladder cancer"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Intravesical administration of Bacillus Calmette-Guérin (BCG), a live attenuated strain of <em>Mycobacterium bovis</em> (<em>M. bovis</em> BCG), is an adjunctive therapy for treatment of non-muscle invasive bladder cancer. <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">Intravesical BCG</a> is usually well tolerated; uncommonly, severe local and systemic complications can occur. Risk factors include presence of bladder mucosal damage, presence of immunosuppression, and advanced age. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations include localized and systemic disease; the presentation depends in part on the timing of onset. In general, early-onset infection (≤3 months of BCG instillation) often presents with systemic manifestations including fever, night sweats, weight loss, pneumonitis, and hepatitis. Delayed-onset infection (&gt;3 months after BCG instillation) often presents with localized disease and positive urine acid-fast bacilli (AFB) cultures. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Definitive diagnosis of BCG infection may be established via positive <em>M. bovis</em> BCG culture (of bodily fluids and/or tissue from involved sites); however, the sensitivity of culture is subject to limitations. In the appropriate clinical and epidemiologic setting and in the absence of evidence for an alternative etiology of these findings, a presumptive diagnosis may be made in the setting of positive AFB smear (of bodily fluids or tissue from involved sites), histopathology from an involved site demonstrating granulomas, and/or positive nucleic acid amplification (NAA) test on fluid or tissue. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnostic evaluation includes obtaining bodily fluids (urine, blood, and fluid from any other involved sites) for AFB stain, mycobacterial culture, mycobacterial NAA test, Gram stain, bacterial culture, fungal stain, and fungal culture, as well as other studies guided by the fluid type. In addition, patients with systemic symptoms should have chest imaging to evaluate for pulmonary involvement. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal antimycobacterial regimen for treatment of <em>M. bovis</em> BCG infection is uncertain. Management should include involvement of an expert in management of mycobacterial infections. We treat patients with <em>M. bovis </em>BCG infection secondary to <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> therapy with the same antimycobacterial medications used to treat <em>M. bovis</em> infection from other sources. Specifically, this includes an initial phase of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">ethambutol</a>, followed by a continuation phase of isoniazid and rifampin, as discussed elsewhere (see  <a class="medical medical_review" href="/z/d/html/8006.html" rel="external">"Mycobacterium bovis", section on 'Treatment'</a>). If susceptibility data are available, the regimen should be tailored accordingly. The duration of therapy depends on disease severity and clinical response. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional treatment considerations for those with <em>M. bovis </em>BCG infection secondary to <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> therapy depend on the presentation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In cases of extensive miliary involvement and/or respiratory failure in which hypersensitivity is thought to play a significant role in the patient’s illness, we suggest concomitant glucocorticoid therapy if potential benefit is felt likely to outweigh potential risk (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Systemic disease'</a> above.)  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical evaluation is warranted in the setting of abscess, genitourinary tract obstruction, vascular infection, or infection involving a prosthetic device. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients presenting with reactive arthritis or uveitis only, <strong>without </strong>signs of localized or systemic infection, antimycobacterial treatment is not administered. The approach to patients with reactive arthritis and uveitis, in general, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7794.html" rel="external">"Reactive arthritis", section on 'Treatment of arthritis'</a> and  <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">"Uveitis: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among individuals with infectious complications due to intravesicular BCG, the risk of repeat BCG administration is uncertain. For patients who have experienced systemic BCG infection, we advise against repeat use of <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a> given potential risk of a recurrent episode. (See <a class="local">'Further cancer treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no proven interventions for preventing infectious complications associated with administration <a class="drug drug_general" data-topicid="102734" href="/z/d/drug information/102734.html" rel="external">intravesical BCG</a>. Patients with breaks in the urogenital epithelium (due to traumatic catheterization, active cystitis, or persistent gross hematuria following transurethral surgery) should have BCG instillation deferred for at least two to three weeks. We suggest against routine prophylactic administration of antimycobacterial therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), when treating with intravesical BCG. Such an intervention has not been shown to be effective and could reduce the antitumor effect of BCG, given that live BCG requires replication to induce a host immune response. (See <a class="local">'Prevention'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 2014; 93:236.</a></li><li><a class="nounderline abstract_t">Green DB, Kawashima A, Menias CO, et al. Complications of Intravesical BCG Immunotherapy for Bladder Cancer. Radiographics 2019; 39:80.</a></li><li><a class="nounderline abstract_t">Marques M, Vazquez D, Sousa S, et al. Disseminated Bacillus Calmette-Guérin (BCG) infection with pulmonary and renal involvement: A rare complication of BCG immunotherapy. A case report and narrative review. Pulmonology 2020; 26:346.</a></li><li><a class="nounderline abstract_t">Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int 2013; 112:288.</a></li><li><a class="nounderline abstract_t">Larsen ES, Nordholm AC, Lillebaek T, et al. The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int 2019; 124:910.</a></li><li><a class="nounderline abstract_t">Pearl R. Cancer and tuberculosis. Am J Epidemiol 1929; 9:97.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-1998. A 57-year-old man with fever and jaundice after intravesical instillation of bacille Calmette-Guérin for bladder cancer. N Engl J Med 1998; 339:831.</a></li><li><a class="nounderline abstract_t">Elkabani M, Greene JN, Vincent AL, et al. Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer. Cancer Control 2000; 7:476.</a></li><li><a class="nounderline abstract_t">McParland C, Cotton DJ, Gowda KS, et al. Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Guérin immunotherapy. Am Rev Respir Dis 1992; 146:1330.</a></li><li><a class="nounderline abstract_t">Kristjansson M, Green P, Manning HL, et al. Molecular confirmation of bacillus Calmette-Guérin as the cause of pulmonary infection following urinary tract instillation. Clin Infect Dis 1993; 17:228.</a></li><li><a class="nounderline abstract_t">Soylu A, Ince AT, Polat H, et al. Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin. Ann Clin Microbiol Antimicrob 2009; 8:12.</a></li><li><a class="nounderline abstract_t">Fradet V, Gaudreau C, Perrotte P, et al. Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer. Can Urol Assoc J 2007; 1:269.</a></li><li><a class="nounderline abstract_t">Alvarez-Múgica M, Gómez JM, Vázquez VB, et al. Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature. J Med Case Rep 2009; 3:7323.</a></li><li><a class="nounderline abstract_t">Hakim S, Heaney JA, Heinz T, Zwolak RW. Psoas abscess following intravesical bacillus Calmette-Guerin for bladder cancer: a case report. J Urol 1993; 150:188.</a></li><li><a class="nounderline abstract_t">Hellinger WC, Oldenburg WA, Alvarez S. Vascular and other serious infections with Mycobacterium bovis after bacillus of Calmette-Guérin therapy for bladder cancer. South Med J 1995; 88:1212.</a></li><li><a class="nounderline abstract_t">Rohailla S, Kitchlu A, Wheatcroft M, Razak F. Mycotic aneurysm formation after bacillus Calmette-Guérin instillation for recurrent bladder cancer. CMAJ 2018; 190:E467.</a></li><li><a class="nounderline abstract_t">Viallard JF, Denis D, Texier-Maugein J, et al. Disseminated infection after bacille Calmette-Guérin instillation for treatment of bladder carcinoma. Clin Infect Dis 1999; 29:451.</a></li><li><a class="nounderline abstract_t">Han DP, Simons KB, Tarkanian CN, Moretti ST. Endophthalmitis from Mycobacterium bovis-bacille Calmette-Guérin after intravesicular bacille Calmette-Guérin injections for bladder carcinoma. Am J Ophthalmol 1999; 128:648.</a></li><li><a class="nounderline abstract_t">Gerbrandy SJ, Schreuders LC, de Smet MD. Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer. Ocul Immunol Inflamm 2008; 16:95.</a></li><li><a class="nounderline abstract_t">Golub V, Malhotra P, Patel S. Mycobacterial brain tuberculomas due to Bacille Calmette-Guérin intravesical chemotherapy for bladder cancer: A case report and literature review. Can J Infect Dis Med Microbiol 2011; 22:104.</a></li><li><a class="nounderline abstract_t">Wolf YG, Wolf DG, Higginbottom PA, Dilley RB. Infection of a ruptured aortic aneurysm and an aortic graft with bacille Calmette-Guérin after intravesical administration for bladder cancer. J Vasc Surg 1995; 22:80.</a></li><li><a class="nounderline abstract_t">Wansaula Z, Wortham JM, Mindra G, et al. Bacillus Calmette-Guérin Cases Reported to the National Tuberculosis Surveillance System, United States, 2004-2015. Emerg Infect Dis 2019; 25:451.</a></li><li><a class="nounderline abstract_t">Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147:596.</a></li><li><a class="nounderline abstract_t">Izes JK, Bihrle W 3rd, Thomas CB. Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin. J Urol 1993; 150:1498.</a></li><li><a class="nounderline abstract_t">Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. Urol Oncol 2008; 26:137.</a></li><li><a class="nounderline abstract_t">Catalona WJ, Ratliff TL. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action. Surg Annu 1990; 22:363.</a></li><li><a class="nounderline abstract_t">Ströck V, Dotevall L, Sandberg T, et al. Late bacille Calmette-Guérin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment. BJU Int 2011; 107:1592.</a></li><li><a class="nounderline abstract_t">Mavrogenis AF, Sakellariou VI, Tsiodras S, Papagelopoulos PJ. Late Mycobacterium bovis spondylitis after intravesical BCG therapy. Joint Bone Spine 2009; 76:296.</a></li><li><a class="nounderline abstract_t">Westhovens IM, Vanden Abeele ME, Messiaen PE, van der Hilst JCh. Systemic BCG infection in a patient with pancytopaenia and fever 9 years after intravesical BCG administration for bladder cancer. BMJ Case Rep 2016; 2016.</a></li><li><a class="nounderline abstract_t">Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003; 36:140.</a></li><li><a class="nounderline abstract_t">Yong C, Steinberg RL, O'Donnell MA. Severe Infectious Complications of Intravesical Bacillus Calmette-Guérin: A Case Series of 10 Patients. Urology 2020; 137:79.</a></li><li><a class="nounderline abstract_t">Dammert P, Boujaoude Z, Rafferty W, Kass J. Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Mehta AR, Mehta PR, Mehta RL. A cough conundrum in a patient with a previous history of BCG immunotherapy for bladder cancer. BMJ Case Rep 2012; 2012.</a></li><li><a class="nounderline abstract_t">Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 1986; 135:272.</a></li><li><a class="nounderline abstract_t">Lamm DL. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am 1992; 19:565.</a></li><li><a class="nounderline abstract_t">French CG, Hickey L, Bell DG. Caseating granulomas on the glans penis as a complication of bacille calmette-guérin intravesical therapy. Rev Urol 2001; 3:36.</a></li><li><a class="nounderline abstract_t">Menke JJ, Heins JR. Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy. Ann Pharmacother 2000; 34:479.</a></li><li><a class="nounderline abstract_t">Ceylan OM, Durukan AH, Uysal Y, et al. Ocular Complications of Intravesicular BCG Treatment for Bladder Carcinoma. Ocul Immunol Inflamm 2022; 30:111.</a></li><li><a class="nounderline abstract_t">Wittes R, Klotz L, Kosecka U. Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail. J Urol 1999; 161:1568.</a></li><li><a class="nounderline abstract_t">LaFontaine PD, Middleman BR, Graham SD Jr, Sanders WH. Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology 1997; 49:363.</a></li><li><a class="nounderline abstract_t">Leibovici D, Zisman A, Chen-Levyi Z, et al. Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin. J Urol 2000; 164:1546.</a></li><li><a class="nounderline abstract_t">Rival G, Garot D, Mercier E, et al. [Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy]. Presse Med 2006; 35:980.</a></li><li><a class="nounderline abstract_t">Ziegler J, Ho J, Gibson IW, et al. Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer. Transpl Infect Dis 2018; 20:e12931.</a></li><li><a class="nounderline abstract_t">Choi CH, Lee SO, Smith G. Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder. BMJ Case Rep 2014; 2014.</a></li><li><a class="nounderline abstract_t">Mignon F, Chevrière A, Mesurolle B, et al. [Miliary induced by intravesical BCG immunotherapy for carcinoma of the bladder: CT Findings]. J Radiol 2002; 83:368.</a></li><li><a class="nounderline abstract_t">Rachakonda T, Kendall B, Spivak AM, Boltax J. Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer. Open Forum Infect Dis 2017; 4:ofx126.</a></li><li><a class="nounderline abstract_t">Proctor DD, Chopra S, Rubenstein SC, et al. Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma. Am J Gastroenterol 1993; 88:1112.</a></li><li><a class="nounderline abstract_t">Thompson D, Cumming J. Granulomatous hepatitis following intravesical BCG therapy. Br J Urol 1990; 66:432.</a></li><li><a class="nounderline abstract_t">Modesto A, Marty L, Suc JM, et al. Renal complications of intravesical bacillus Calmette-Guérin therapy. Am J Nephrol 1991; 11:501.</a></li><li><a class="nounderline abstract_t">Kamphuis JT, Buiting AG, Miseré JF, et al. BCG immunotherapy: be cautious of granulomas. Disseminated BCG infection and mycotic aneurysm as late complications of intravesical BCG instillations. Neth J Med 2001; 58:71.</a></li><li><a class="nounderline abstract_t">Katz DS, Wogalter H, D'Esposito RF, Cunha BA. Mycobacterium bovis vertebral osteomyelitis and psoas abscess after intravesical BCG therapy for bladder carcinoma. Urology 1992; 40:63.</a></li><li><a class="nounderline abstract_t">Fishman JR, Walton DT, Flynn NM, et al. Tuberculous spondylitis as a complication of intravesical bacillus Calmette-Guerin therapy. J Urol 1993; 149:584.</a></li><li><a class="nounderline abstract_t">Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol 1999; 37:2106.</a></li><li><a class="nounderline abstract_t">Kusakabe T, Endo K, Nakamura I, et al. Bacille Calmette-Guérin (BCG) spondylitis with adjacent mycotic aortic aneurysm after intravesical BCG therapy: a case report and literature review. BMC Infect Dis 2018; 18:290.</a></li><li><a class="nounderline abstract_t">Clavel G, Grados F, Lefauveau P, Fardellone P. Osteoarticular side effects of BCG therapy. Joint Bone Spine 2006; 73:24.</a></li><li><a class="nounderline abstract_t">Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 2006; 26:481.</a></li><li><a class="nounderline abstract_t">Miranda S, Verdet M, Héron F, et al. [Acute reactive arthritis after intravesical instillation of bacillus Calmette-Guérin. Two case reports and literature review]. Rev Med Interne 2010; 31:558.</a></li><li><a class="nounderline abstract_t">Ng KL, Chua CB. Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations. Asian J Surg 2017; 40:163.</a></li><li><a class="nounderline abstract_t">Guerra CE, Betts RF, O'Keefe RJ, Shilling JW. Mycobacterium bovis osteomyelitis involving a hip arthroplasty after intravesicular bacille Calmette-Guérin for bladder cancer. Clin Infect Dis 1998; 27:639.</a></li><li><a class="nounderline abstract_t">Segal A, Krauss ES. Infected total hip arthroplasty after intravesical bacillus Calmette-Guérin therapy. J Arthroplasty 2007; 22:759.</a></li><li><a class="nounderline abstract_t">Reigstad O, Siewers P. A total hip replacement infected with mycobacterium bovis after intravesicular treatment with Bacille-Calmette-Guérin for bladder cancer. J Bone Joint Surg Br 2008; 90:225.</a></li><li><a class="nounderline abstract_t">Rosevear HM, Lightfoot AJ, Nepple KG, O'Donnell MA. Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices. J Urol 2010; 184:1920.</a></li><li><a class="nounderline abstract_t">Coscas R, Arlet JB, Belhomme D, et al. Multiple mycotic aneurysms due to Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy. J Vasc Surg 2009; 50:1185.</a></li><li><a class="nounderline abstract_t">Granel B, Serratrice J, Morange PE, et al. Cryoglobulinemia vasculitis following intravesical instillations of bacillus Calmette-Guerin. Clin Exp Rheumatol 2004; 22:481.</a></li><li><a class="nounderline abstract_t">Misra S, Gupta A, Symes A, Duncan J. Haemophagocytic syndrome after intravesical bacille Calmette-Guérin instillation. Scand J Urol 2014; 48:328.</a></li><li><a class="nounderline abstract_t">Sheron MW, Holt SL, Ingram CW. Mycobacterium bovis Cerebellar Abscess Following Treatment With Bacillus Calmette-Guérin. J Pharm Pract 2017; 30:378.</a></li><li><a class="nounderline abstract_t">Parent ME, Richer M, Liang P. The first case of bacillus Calmette-Guérin-induced small-vessel central nervous system vasculitis. Clin Rheumatol 2018; 37:2297.</a></li><li><a class="nounderline abstract_t">Rock RB, Olin M, Baker CA, et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008; 21:243.</a></li><li><a class="nounderline abstract_t">Lowther C, Miedler JD, Cockerell CJ. Id-like reaction to BCG therapy for bladder cancer. Cutis 2013; 91:145.</a></li><li><a class="nounderline abstract_t">Larsen ES, Joensen UN, Poulsen AM, et al. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. APMIS 2020; 128:92.</a></li><li><a class="nounderline abstract_t">Smith JA Jr, Labasky RF, Cockett AT, et al. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1999; 162:1697.</a></li><li><a class="nounderline abstract_t">Silverman MS, Reynolds D, Kavsak PA, et al. Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis. Clin Biochem 2007; 40:913.</a></li><li><a class="nounderline abstract_t">Durek C, Rüsch-Gerdes S, Jocham D, Böhle A. Sensitivity of BCG to modern antibiotics. Eur Urol 2000; 37 Suppl 1:21.</a></li><li><a class="nounderline abstract_t">Steg A, Leleu C, Debré B, et al. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res 1989; 310:325.</a></li><li><a class="nounderline abstract_t">Molina JM, Rabian C, D'Agay MF, Modai J. Hypersensitivity systemic reaction following intravesical bacillus Calmette-Guerin: successful treatment with steroids. J Urol 1992; 147:695.</a></li><li><a class="nounderline abstract_t">Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31 Suppl 3:S86.</a></li><li><a class="nounderline abstract_t">Zhao LC, Meeks JJ, Helfand BT, et al. Screening urine analysis before bacille Calmette-Guérin instillation does not reduce the rate of infectious complications. BJU Int 2012; 109:1819.</a></li><li><a class="nounderline abstract_t">Herr HW. Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria. BJU Int 2012; 110:E658.</a></li><li><a class="nounderline abstract_t">van der Meijden AP, Brausi M, Zambon V, et al. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 2001; 166:476.</a></li></ol></div><div id="topicVersionRevision">Topic 2973 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398060" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30526332" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Complications of Intravesical BCG Immunotherapy for Bladder Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711964" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Disseminated Bacillus Calmette-Guérin (BCG) infection with pulmonary and renal involvement: A rare complication of BCG immunotherapy. A case report and narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23517232" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31054198" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cancer and tuberculosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9750077" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-1998. A 57-year-old man with fever and jaundice after intravesical instillation of bacille Calmette-Guérin for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11000618" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1443892" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Guérin immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8104511" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular confirmation of bacillus Calmette-Guérin as the cause of pulmonary infection following urinary tract instillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368735" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18542802" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19918272" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder cancer: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8510250" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Psoas abscess following intravesical bacillus Calmette-Guerin for bladder cancer: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7502112" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vascular and other serious infections with Mycobacterium bovis after bacillus of Calmette-Guérin therapy for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29661816" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mycotic aneurysm formation after bacillus Calmette-Guérin instillation for recurrent bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10476764" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Disseminated infection after bacille Calmette-Guérin instillation for treatment of bladder carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10577542" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Endophthalmitis from Mycobacterium bovis-bacille Calmette-Guérin after intravesicular bacille Calmette-Guérin injections for bladder carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18569795" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22942888" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mycobacterial brain tuberculomas due to Bacille Calmette-Guérin intravesical chemotherapy for bladder cancer: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7602717" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Infection of a ruptured aortic aneurysm and an aortic graft with bacille Calmette-Guérin after intravesical administration for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30789145" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bacillus Calmette-Guérin Cases Reported to the National Tuberculosis Surveillance System, United States, 2004-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538436" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8411436" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312931" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2408170" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21166754" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Late bacille Calmette-Guérin infection with a large focal urinary bladder ulceration as a complication of bladder cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19303342" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Late Mycobacterium bovis spondylitis after intravesical BCG therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27170615" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Systemic BCG infection in a patient with pancytopaenia and fever 9 years after intravesical BCG administration for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522745" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31705946" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Severe Infectious Complications of Intravesical Bacillus Calmette-Guérin: A Case Series of 10 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23576657" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23097577" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A cough conundrum in a patient with a previous history of BCG immunotherapy for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511286" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1636240" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Complications of bacillus Calmette-Guérin immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985688" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Caseating granulomas on the glans penis as a complication of bacille calmette-guérin intravesical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10772435" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32835567" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ocular Complications of Intravesicular BCG Treatment for Bladder Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10210404" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Severe bacillus Calmette-Guerin cystitis responds to systemic steroids when antituberculous drugs and local steroids fail.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9123699" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025701" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16783258" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : [Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29809299" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24811557" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11979232" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : [Miliary induced by intravesical BCG immunotherapy for carcinoma of the bladder: CT Findings].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28761898" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8317415" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2224441" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Granulomatous hepatitis following intravesical BCG therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1819218" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Renal complications of intravesical bacillus Calmette-Guérin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11166448" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : BCG immunotherapy: be cautious of granulomas. Disseminated BCG infection and mycotic aneurysm as late complications of intravesical BCG instillations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1621315" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mycobacterium bovis vertebral osteomyelitis and psoas abscess after intravesical BCG therapy for bladder carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8437271" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Tuberculous spondylitis as a complication of intravesical bacillus Calmette-Guerin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325395" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29954321" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bacille Calmette-Guérin (BCG) spondylitis with adjacent mycotic aortic aneurysm after intravesical BCG therapy: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461205" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Osteoarticular side effects of BCG therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16220289" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20494494" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : [Acute reactive arthritis after intravesical instillation of bacillus Calmette-Guérin. Two case reports and literature review].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25183290" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770167" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mycobacterium bovis osteomyelitis involving a hip arthroplasty after intravesicular bacille Calmette-Guérin for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17689788" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Infected total hip arthroplasty after intravesical bacillus Calmette-Guérin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256093" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A total hip replacement infected with mycobacterium bovis after intravesicular treatment with Bacille-Calmette-Guérin for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846678" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferonα-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19660898" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Multiple mycotic aneurysms due to Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301249" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cryoglobulinemia vasculitis following intravesical instillations of bacillus Calmette-Guerin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24070063" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Haemophagocytic syndrome after intravesical bacille Calmette-Guérin instillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26966140" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mycobacterium bovis Cerebellar Abscess Following Treatment With Bacillus Calmette-Guérin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29740727" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The first case of bacillus Calmette-Guérin-induced small-vessel central nervous system vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18400795" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Central nervous system tuberculosis: pathogenesis and clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23617086" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Id-like reaction to BCG therapy for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31755155" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524909" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17512514" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575268" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sensitivity of BCG to modern antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2672020" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538462" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hypersensitivity systemic reaction following intravesical bacillus Calmette-Guerin: successful treatment with steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11010830" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077819" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Screening urine analysis before bacille Calmette-Guérin instillation does not reduce the rate of infectious complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22883017" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11458050" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
